Mucinous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCN001 MIFTS: 48	Mucinous Adenocarcinoma Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma ¹¹ ¹⁴ ⁷¹

Mucin-Producing Adenocarcinoma ¹¹ ⁷¹

Pseudomyxoma Peritonei with Unknown Primary Site ¹¹

Mucin-Secreting Adenocarcinoma ¹¹

Mucin-Secreting Carcinoma ¹¹

Adenocarcinoma, Mucinous ⁴³

Mucous Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3030

MeSH ⁴³ D002288

NCIt ⁴⁹ C26712 C27379

SNOMED-CT ⁶⁸ 72495009 900006

UMLS ⁷¹ C0007130 C0334368

Sources

Summaries for Mucinous Adenocarcinoma

Disease Ontology: ¹¹ An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary: Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to cervical mucinous adenocarcinoma and bile duct mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is CHST4 (Carbohydrate Sulfotransferase 4), and among its related pathways/superpathways are Disease and TCR Signaling (Qiagen). The drugs Irinotecan and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are Increased cell migration and Synthetic lethal with vaccinia virus (VACV) infection

Sources

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 779)

#	Related Disease	Score	Top Affiliating Genes
1	cervical mucinous adenocarcinoma	32.6	NAPSA MUC6 KRT7
2	bile duct mucinous adenocarcinoma	32.6	TP53 MUC5AC
3	ovarian mucinous adenocarcinoma	32.5	MUC5AC KRT7 KRT20 CHST4 CEACAM5 CDX2
4	appendix adenocarcinoma	32.4	TP53 MSH6 KRT7 KRT20 KRAS HRAS
5	pseudomyxoma peritonei	31.9	TP53 MUC6 MUC5AC KRT7 KRT20 KRAS
6	renal pelvis adenocarcinoma	31.1	KRT7 CEACAM5
7	thymus adenocarcinoma	31.0	KRT20 CEACAM5 CDX2
8	appendiceal neoplasm	30.9	KRT7 KRAS HRAS CEACAM5 CDX2
9	intestinal obstruction	30.9	KRT7 KRT20 CEACAM5 CDX2
10	bladder adenocarcinoma	30.9	TP53 NAPSA KRT7 KRT20 CEACAM5 CDX2
11	pancreatic adenocarcinoma	30.8	TP53 KRAS HRAS ERBB2 EGFR
12	anus adenocarcinoma	30.8	MUC5AC KRT7 CDX2
13	benign teratoma	30.8	TP53 NKX2-1 KRT7 KRT20 CEACAM5 CDX2
14	cystic teratoma	30.8	TP53 NKX2-1 KRT7 KRT20 CEACAM5 CDX2
15	colon adenocarcinoma	30.8	TP53 MSH6 MLH1 KRT20 KRAS HRAS
16	anal canal adenocarcinoma	30.8	MUC5AC KRT7 KRT20 CDX2
17	cervical adenocarcinoma	30.8	TP53 MUC5AC KRT7 KRT20 KRAS CEACAM5
18	mammary paget's disease	30.7	KRT7 KRT20 ERBB2 CEACAM5
19	neuroendocrine carcinoma	30.7	NKX2-1 KRT7 KRT20
20	cystadenocarcinoma	30.7	TP53 MUC5AC KRT7 KRAS CEACAM5
21	thymic carcinoma	30.7	NKX2-1 KRT7 EGFR
22	vulva adenocarcinoma	30.7	KRT7 KRT20 ERBB2 CEACAM5 CDX2
23	clear cell adenocarcinoma	30.7	TP53 NAPSA KRT7
24	peutz-jeghers syndrome	30.7	TP53 MUC6 MUC5AC EGFR
25	suppression of tumorigenicity 12	30.7	TP53 HRAS ERBB2 EGFR
26	ovary adenocarcinoma	30.6	TP53 MLH1 KRT7 KRAS HRAS ERBB2
27	bladder urachal carcinoma	30.6	KRT7 KRAS HRAS CDX2
28	teratoma	30.6	TP53 NKX2-1 KRT7 KRT20 KRAS ERBB2
29	diffuse gastric cancer	30.6	TP53 PMS2 MSH6 MSH2 MLH1 KRAS
30	cystadenoma	30.6	MUC6 MUC5AC KRT7 KRT20 CEACAM5
31	cystitis	30.6	TP53 KRT7 KRT20
32	mucoepidermoid carcinoma	30.6	MUC5AC KRT7 EGFR
33	adenocarcinoma	30.5	TP53 NKX2-1 NAPSA MUC5AC MSH6 MSH2
34	endometrial adenocarcinoma	30.5	TP53 PMS2 MSH6 MSH2 MLH1 KRT7
35	rectum cancer	30.5	TP53 MSH6 MSH2 MLH1 KRT20 KRAS
36	mature teratoma	30.5	TP53 KRT7 CEACAM5 CDX2
37	benign mesothelioma	30.4	NKX2-1 KRT7 KRT20 CEACAM5
38	lobular neoplasia	30.4	TP53 ERBB2 EGFR
39	mucinous lung adenocarcinoma	30.4	NKX2-1 NAPSA KRAS HRAS EGFR ALK
40	cholecystitis	30.4	TP53 MUC6 MUC5AC EGFR
41	vulva cancer	30.4	TP53 KRT7 HRAS ERBB2 EGFR CEACAM5
42	transverse colon cancer	30.4	PMS2 MLH1 KRT20 KRAS HRAS CEACAM5
43	nephrogenic adenoma	30.4	NAPSA KRT7
44	endocervical adenocarcinoma	30.3	TP53 MUC6 MSH6 KRT7 HRAS ERBB2
45	esophagus adenocarcinoma	30.3	TP53 ERBB2 EGFR CDX2
46	blastoma	30.3	TP53 NKX2-1 KRT7 KRAS HRAS EGFR
47	papillary carcinoma	30.3	NKX2-1 KRT7 KRT20 ERBB2
48	struma ovarii	30.3	NKX2-1 KRT7 KRAS
49	ovarian germ cell cancer	30.3	NKX2-1 KRT7 CEACAM5
50	papillary cystadenocarcinoma	30.3	TP53 KRT7 KRT20

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:

Sources

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell migration	GR00055-A-1	9.26	NEK8
2	Increased cell migration	GR00055-A-3	9.26	NEK8
3	Synthetic lethal with vaccinia virus (VACV) infection	GR00362-A	8.62	MSH6 NEK8

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.31	ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
2	neoplasm	MP:0002006	10.25	ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
3	digestive/alimentary	MP:0005381	10.13	CDX2 CEACAM5 EGFR ERBB2 HRAS KRAS
4	endocrine/exocrine gland	MP:0005379	10.11	ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
5	cellular	MP:0005384	10.07	CDX2 CEACAM5 CHST4 EGFR ERBB2 KRAS
6	respiratory system	MP:0005388	9.81	ALK EGFR ERBB2 HRAS KRAS MLH1
7	mortality/aging	MP:0010768	9.8	ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
8	integument	MP:0010771	9.28	ALK EGFR ERBB2 HRAS KRAS MLH1

Sources

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Camptothecin

Experimental

Phase 3

7689-03-4

24360

Edrecolomab

Investigational

Phase 3

156586-89-9

Paclitaxel poliglumex

Experimental, Investigational

Phase 3

263351-82-2

Carotenoids

Phase 3

topoisomerase I inhibitors

Phase 3

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Adjuvants, Immunologic

Phase 3

Immunoglobulins, Intravenous

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Immunoglobulin G

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antibodies, Monoclonal

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Angiogenesis Inhibitors

Phase 3

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Trace Elements

Phase 3

Micronutrients

Phase 3

Cola

Phase 3

Taxane

Phase 3

108169

Vitamins

Phase 3

Hormones

Phase 3

Calcium, Dietary

Phase 3

Hematinics

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Panitumumab

Approved, Investigational

Phase 2

339177-26-3

Cetuximab

Approved

Phase 2

205923-56-4

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Olaparib

Approved

Phase 2

763113-22-0

23725625

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Iodine

Approved, Investigational

Phase 1, Phase 2

7553-56-2

807

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Acetylcysteine

Approved, Investigational

Phase 2

616-91-1

581 12035

Nivolumab

Approved

Phase 2

946414-94-4

Interventional clinical trials:

(show top 50) (show all 69)

#	Name	Status	NCT ID	Phase	Drugs
1	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
2	A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
3	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Completed	NCT00951496	Phase 3	Carboplatin;Cisplatin;Paclitaxel
4	A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU	Completed	NCT00005036	Phase 3	irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
5	Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil	Completed	NCT00068692	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
6	Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon	Completed	NCT00002968	Phase 3
7	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
8	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
9	GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
10	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	Active, not recruiting	NCT00217737	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin
11	A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer	Unknown status	NCT01652196	Phase 2	oxaliplatin;leucovorin;fluorouracil
12	A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.	Unknown status	NCT01814501	Phase 2	irinotecan hydrochloride;fluorouracil;leucovorin calcium
13	A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)	Unknown status	NCT04446091	Phase 1, Phase 2	Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
14	Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?	Unknown status	NCT01037049	Phase 2
15	A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma	Completed	NCT01097746	Phase 2	Carboplatin;Paclitaxel
16	A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	NCT00888615	Phase 2	Elesclomol Sodium;Paclitaxel
17	A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT02853318	Phase 2	Cyclophosphamide
18	A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation	Completed	NCT01802320	Phase 2	Akt Inhibitor MK2206
19	A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT02923739	Phase 2	Paclitaxel
20	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
21	Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	Completed	NCT00100841	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
22	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
23	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
24	A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab	Recruiting	NCT04739800	Phase 2	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
25	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
26	Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer	Recruiting	NCT02068794	Phase 1, Phase 2
27	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
28	A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma	Recruiting	NCT05112601	Phase 2
29	METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin	Recruiting	NCT05504252	Phase 2	Nivolumab;Oxaliplatin
30	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Recruiting	NCT02978625	Phase 2
31	Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer	Active, not recruiting	NCT01871571	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
32	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Active, not recruiting	NCT00492778	Phase 2	Cisplatin
33	A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies	Active, not recruiting	NCT03602079	Phase 1, Phase 2	A166
34	A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei	Not yet recruiting	NCT03976973	Phase 2	Bromelain;Acetylcysteine
35	Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring	Not yet recruiting	NCT05500391	Phase 2
36	A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors	Terminated	NCT03693846	Phase 2	Nivolumab;Ipilimumab
37	A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer	Terminated	NCT00052585	Phase 2	irinotecan hydrochloride;gefitinib;leucovorin calcium;fluorouracil
38	Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer	Terminated	NCT00002796	Phase 1, Phase 2	fluorouracil;sodium phenylbutyrate;indomethacin
39	A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer	Terminated	NCT00745134	Phase 2	Capecitabine
40	Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer	Withdrawn	NCT02235324	Phase 2	leucovorin calcium;fluorouracil
41	Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer	Completed	NCT01923337	Phase 1	irinotecan hydrochloride;alisertib
42	A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies	Completed	NCT01643499	Phase 1	oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
43	A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	NCT00989651	Phase 1	Carboplatin;Cisplatin;Paclitaxel;Veliparib
44	A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT01074411	Phase 1	Bortezomib;Carboplatin
45	A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer	Completed	NCT00060411	Phase 1	erlotinib hydrochloride;fluorouracil;leucovorin calcium;oxaliplatin
46	Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies	Completed	NCT04088786	Phase 1	nanoliposomal irinotecan
47	Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer	Completed	NCT02270606	Phase 1	fluorouracil;oxaliplatin;leucovorin calcium
48	Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma	Completed	NCT00003799	Phase 1	fluorouracil;oxaliplatin;leucovorin calcium
49	Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer	Completed	NCT01440998	Phase 1	Carboplatin;Dasatinib;Paclitaxel
50	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Recruiting	NCT02020707	Phase 1	Nab-paclitaxel

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Sources

Genetic Tests for Mucinous Adenocarcinoma

Sources

Anatomical Context for Mucinous Adenocarcinoma

Organs/tissues related to Mucinous Adenocarcinoma:

MalaCards : Colon, Liver, Lung, Appendix, Lymph Node, Prostate, Ovary

Sources

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 2715)

#	Title	Authors	PMID	Year
1	A massive malignant pleural effusion due to lung adenocarcinoma in an adult male: a case report. ⁶²	Rentiya ZS...Khan AM	36439928	2023
2	Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). ⁶²	Buyuk M...Yilmazbayhan D	36367122	2022
3	Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma. ⁶²	Pang Z...Zhu L	36474376	2022
4	Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea. ⁶²	Woo W...Lee CY	36345148	2022
5	High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action. ⁶²	Healy MA...Chang GJ	33630474	2022
6	Breast metastasis of signet ring cell carcinoma from the colon: a case report. ⁶²	Wang X...Lu Y	36451153	2022
7	Adult Colo-Colonic Intussusception in the Setting of Invasive Mucinous Adenocarcinoma: A Case Report. ⁶²	Kulkarni S...Choi K	36464886	2022
8	Mixed neuroendocrine/Non-neuroendocrine neoplasm (MiNEN) of gastrointestinal lineage arising in an ovarian mature cystic teratoma. ⁶²	Dasaraju S...Khalifa MA	36388757	2022
9	NKX3.1 Expression in Salivary Gland "Intraductal" Papillary Mucinous Neoplasm: A Low-Grade Subtype of Salivary Gland Mucinous Adenocarcinoma. ⁶²	Nakaguro M...Faquin WC	35834096	2022
10	Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification? ⁶²	Rooper LM...Bishop JA	35794510	2022
11	Appendiceal mucinous adenocarcinoma masquerading as acute appendicitis. ⁶²	Huang Y...Cheng T	35732542	2022
12	Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers. ⁶²	Zhang S...Wang X	36461012	2022
13	MUC6 distribution in the spectrum of pulmonary mucinous adenocarcinoma. ⁶²	Pelosi G...Sonzogni A	36071099	2022
14	Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix. ⁶²	Jian D...Feng Y	36122512	2022
15	Defining the spatial landscape of KRAS mutated congenital pulmonary airway malformations: a distinct entity with a spectrum of histopathologic features. ⁶²	Nelson ND...Pogoriler J	35794233	2022
16	Prevention of radiation enteritis by interposition of an intra-abdominal spacer before irradiation of an appendiceal tumour abscess drainage route. ⁶²	Al Chirazi N...Pocard M	35853802	2022
17	Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma. ⁶²	Okada F...Ohbayashi C	36456172	2022
18	Tumor Depth Prediction of Gastric Cancer With a T4 Score. ⁶²	Taniguchi K...Yamamoto M	36340460	2022
19	The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. ⁶²	Zhao W...Tan R	36428700	2022
20	Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm. ⁶²	Yamaoka Y...Notsu A	36283994	2022
21	Neonatal congenital pulmonary airway malformation associated with mucinous adenocarcinoma and KRAS mutations. ⁶²	Muntean A...Davenport M	34980466	2022
22	A refined prediction of early recurrence combining tumor deposits in patients with resected rectal mucinous adenocarcinoma. ⁶²	Sun Y...Chi P	36357597	2022
23	Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. ⁶²	Dursun F...Satkunasivam R	35509235	2022
24	Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion. ⁶²	Park BJ...Lee CY	36436241	2022
25	A prognostic nomogram for predicting overall survival in colorectal mucinous adenocarcinoma patients based on the SEER database. ⁶²	Wu Q...Gao W	36373623	2022
26	[A tumor of the uterus with a falsely benign aspect]. ⁶²	Tauziede-Espariat A...Georges O	35034828	2022
27	Colonic mucinous adenocarcinoma in a tufted deer: differential diagnosis and literature review. ⁶²	Gonzalez-Astudillo V...Uzal FA	36056527	2022
28	The appendix "mucocoele" misnomer: radiological terminology of "likely appendix mucinous neoplasm" better reflects pathology findings. ⁶²	Bhagwanani A...Moran BJ	36411089	2022
29	Cystic Salivary Gland Neoplasms: Diagnostic Approach With a Focus on Ancillary Studies. ⁶²	Ribeiro EA...Maleki Z	36044380	2022
30	The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. ⁶²	Zhao J...Zeng H	36376185	2022
31	Invasive Mucinous Adenocarcinoma of the Lung With a Mural Nodule-like Lesion. ⁶²	Higashiyama M...Yatabe Y	35939825	2022
32	Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. ⁶²	Neyaz A...Deshpande V	35590108	2022
33	Extramural venous invasion and depth of extramural invasion on preoperative CT as prognostic imaging biomarkers in patients with locally advanced ascending colon cancer. ⁶²	Cho J...Park JH	36066635	2022
34	Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma. ⁶²	Woo W...Lee S	35945128	2022
35	A Case of Invasive Mucinous Adenocarcinoma with Acute Respiratory Distress Syndrome Diagnosed by Autopsy Findings. ⁶²	Kawasumi M...Senoo T	36418103	2022
36	[Relationship of diffusion kurtosis imaging parameters with the pathologic type and prognosis of rectal tumors]. ⁶²	Li J...Cheng JL	36380670	2022
37	Retroperitoneal mass, a rare manifestation of mucinous adenocarcinoma of appendix: A case report. ⁶²	Salehipour M...Kiani S	36415704	2022
38	Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis. ⁶²	Zhang Y...Xiao S	35768312	2022
39	Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature. ⁶²	Hall KC...Berning A	36305517	2022
40	The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis. ⁶²	E Y...Zheng HC	36255176	2022
41	Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. ⁶²	Zhao T...Wu CL	35926810	2022
42	Mucinous adenocarcinoma arising from a tailgut cyst: A case report. ⁶²	Malliou P...Paramythiotis D	36337315	2022
43	Locally advanced rectal mucinous adenocarcinoma: is preoperative radiation necessary? ⁶²	Li B...Cao W	36388693	2022
44	Diffusion-Weighted MRI as Non-Invasive Diagnostic Tool for Rectal Cancer Aggressiveness and Correlation with KI-67 Expression in Tumor Tissue. ⁶²	El Sayed FM...Abosaif AI	36308363	2022
45	Quantitative T2 Mapping to Discriminate Mucinous from Nonmucinous Adenocarcinoma in Rectal Cancer: Comparison with Diffusion-weighted Imaging. ⁶²	Zhang J...Hu S	34421090	2022
46	Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. ⁶²	Bhagat M...Green J	36164316	2022
47	Retroperitoneal primary adenocarcinoma of Mullerian origin: case report with radiology review. ⁶²	Azeem S...Tchabo N	35965919	2022
48	Development and validation of a prognostic nomogram for patients with stage II colon mucinous adenocarcinoma. ⁶²	Huang J...Xiao S	36149446	2022
49	Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma. ⁶²	Wang P...Ma X	36192778	2022
50	The long-term outcome following thoraco-amniotic shunting for congenital lung malformations. ⁶²	Muntean A...Davenport M	36379747	2022

Sources

Genes for Mucinous Adenocarcinoma

Genes related to Mucinous Adenocarcinoma (0 elite genes):

(show all 32)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CHST4	Carbohydrate Sulfotransferase 4	Protein Coding	21.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
2	KRT7	Keratin 7	Protein Coding	7.85	DISEASES inferred ¹⁴
3	CDX2	Caudal Type Homeobox 2	Protein Coding	7.85	DISEASES inferred ¹⁴
4	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	7.71	DISEASES inferred ¹⁴
5	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.65	DISEASES inferred ¹⁴
6	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	7.58	DISEASES inferred ¹⁴
7	NEK8	NIMA Related Kinase 8	Protein Coding	7.27	GeneCards inferred via : Expressions (show sections)
8	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	7.21	DISEASES inferred ¹⁴
9	KRT20	Keratin 20	Protein Coding	7.17	DISEASES inferred ¹⁴
10	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	7.12	DISEASES inferred ¹⁴
11	EGFR	Epidermal Growth Factor Receptor	Protein Coding	7.05	DISEASES inferred ¹⁴
12	NKX2-1	NK2 Homeobox 1	Protein Coding	7.04	DISEASES inferred ¹⁴
13	TP53	Tumor Protein P53	Protein Coding	6.91	DISEASES inferred ¹⁴
14	MLH1	MutL Homolog 1	Protein Coding	6.88	DISEASES inferred ¹⁴
15	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	6.8	DISEASES inferred ¹⁴
16	MSH2	MutS Homolog 2	Protein Coding	6.71	DISEASES inferred ¹⁴
17	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	6.7	DISEASES inferred ¹⁴
18	MSH6	MutS Homolog 6	Protein Coding	6.69	DISEASES inferred ¹⁴
19	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.67	DISEASES inferred ¹⁴
20	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.64	DISEASES inferred ¹⁴
21	ARFIP2	ADP Ribosylation Factor Interacting Protein 2	Protein Coding	6.48	DISEASES inferred ¹⁴
22	NRG1	Neuregulin 1	Protein Coding	6.47	DISEASES inferred ¹⁴
23	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	6.37	DISEASES inferred ¹⁴
24	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	6.36	DISEASES inferred ¹⁴ ¹⁴
25	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.35	DISEASES inferred ¹⁴
26	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	6.2	DISEASES inferred ¹⁴
27	PAX8	Paired Box 8	Protein Coding	6.18	DISEASES inferred ¹⁴
28	GNAS	GNAS Complex Locus	Protein Coding	6.15	DISEASES inferred ¹⁴
29	CTNNB1	Catenin Beta 1	Protein Coding	6.12	DISEASES inferred ¹⁴
30	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.1	DISEASES inferred ¹⁴
31	SMAD4	SMAD Family Member 4	Protein Coding	5.97	DISEASES inferred ¹⁴
32	CD74	CD74 Molecule	Protein Coding	5.96	DISEASES inferred ¹⁴

Sources

Variations for Mucinous Adenocarcinoma

Sources

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Sources

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 42)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.64	ALK EGFR ERBB2 HRAS KRAS MLH1
2	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.89	TP53 MSH6 MSH2 MLH1 KRAS HRAS
3	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.79	KRAS HRAS ERBB2 EGFR ALK
4	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.5	TP53 MSH2 KRAS HRAS ERBB2 EGFR
5	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.4	EGFR ERBB2 HRAS KRAS TP53
6	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ⁶¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	12.39	MUC6 MUC5AC KRAS HRAS
7	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.39	EGFR ERBB2 HRAS KRAS TP53
8	Base excision repair ⁷⁴ Show member pathways Abasic sugar-phosphate removal via the single-nucleotide replacement pathway ⁶⁶ APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway ⁶⁶ Cell cycle Transition and termination of DNA replication ²² Displacement of DNA glycosylase by APEX1 ⁶⁶ DNA mismatch repair ⁷⁴ Gap-filling DNA repair synthesis and ligation in GG-NER ⁶⁶ Mismatch Repair in Eukaryotes ⁶⁴ PCNA-Dependent Long Patch Base Excision Repair ⁶⁶ POLB-Dependent Long Patch Base Excision Repair ⁶⁶ Resolution of Abasic Sites (AP sites) ⁶⁶ Resolution of AP sites via the multiple-nucleotide patch replacement pathway ⁶⁶ Resolution of AP sites via the single-nucleotide replacement pathway ⁶⁶	12.38	PMS2 MSH6 MSH2 MLH1
9	MAPK signaling pathway ⁷⁴	12.36	TP53 KRAS HRAS EGFR
10	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.36	TP53 KRAS HRAS ERBB2 EGFR
11	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.35	KRAS HRAS ERBB2 EGFR ALK
12	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.22	KRAS HRAS ERBB2 EGFR
13	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.17	TP53 KRAS HRAS ERBB2 EGFR
14	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.13	EGFR ERBB2 HRAS KRAS
15	mTOR Signaling ⁶⁵	12.06	TP53 KRAS ERBB2 EGFR
16	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.03	KRAS HRAS ERBB2 EGFR
17	Integrated breast cancer pathway ⁷⁴	12.03	TP53 MSH6 MSH2 KRAS EGFR
18	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12	KRAS HRAS ERBB2 EGFR
19	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.93	KRAS HRAS ERBB2 EGFR
20	Direct p53 effectors ⁶¹	11.91	TP53 PMS2 MSH2 MLH1 EGFR
21	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	11.9	TP53 MSH6 MSH2 MLH1 KRAS HRAS
22	Colorectal Cancer Metastasis ⁶⁴	11.85	TP53 MSH6 MSH2 MLH1 KRAS EGFR
23	DNA damage response (only ATM dependent) ⁷⁴	11.83	TP53 KRAS HRAS ERBB2
24	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.78	TP53 MSH6 MSH2
25	DNA IR-damage and cellular response via ATR ⁷⁴	11.76	TP53 MSH2 MLH1
26	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.74	HRAS KRAS TP53
27	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.63	TP53 HRAS ERBB2
28	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.53	KRAS HRAS ERBB2 EGFR
29	Head and neck squamous cell carcinoma ⁷⁴	11.52	EGFR ERBB2 HRAS KRAS TP53
30	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.46	KRAS HRAS EGFR
31	Doxorubicin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶⁰	11.41	TP53 MSH2 MLH1
32	Integrated cancer pathway ⁷⁴	11.38	TP53 MSH6 MSH2
33	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.38	KRAS HRAS ALK
34	a6b1 and a6b4 Integrin signaling ⁶¹	11.36	EGFR ERBB2 HRAS
35	Transcription_Transcription factor Tubby signaling pathways ²²	11.25	TP53 KRAS HRAS EGFR
36	Aryl hydrocarbon receptor pathway ⁷⁴	11.24	KRAS HRAS EGFR
37	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.17	KRAS HRAS EGFR
38	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.13	PMS2 MSH6 MSH2 MLH1
39	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.07	KRAS HRAS ERBB2 EGFR
40	Bladder cancer ⁷⁴	10.96	TP53 KRAS HRAS ERBB2 EGFR
41	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.77	KRAS HRAS
42	Defective Mismatch Repair Associated With PMS2 ⁶⁶ Show member pathways Defective Mismatch Repair Associated With MLH1 ⁶⁶	10.25	PMS2 MLH1

Sources

GO Terms for Mucinous Adenocarcinoma

Cellular components related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	MutLalpha complex	GO:0032389	9.46	PMS2 MLH1
2	MutSalpha complex	GO:0032301	9.26	MSH6 MSH2
3	mismatch repair complex	GO:0032300	9.02	PMS2 MSH2 MLH1

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	intrinsic apoptotic signaling pathway	GO:0097193	9.93	TP53 MSH6 HRAS
2	determination of adult lifespan	GO:0008340	9.91	TP53 MSH6 MSH2
3	regulation of cell population proliferation	GO:0042127	9.91	ALK EGFR ERBB2 HRAS TP53
4	positive regulation of helicase activity	GO:0051096	9.81	MSH6 MSH2
5	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.8	MSH2 MLH1
6	isotype switching	GO:0045190	9.8	MSH6 MSH2 MLH1
7	mismatch repair	GO:0006298	9.76	PMS2 MSH6 MSH2 MLH1
8	multicellular organism development	GO:0007275	9.71	ERBB2 EGFR CDX2 ALK
9	maintenance of DNA repeat elements	GO:0043570	9.65	MSH6 MSH2
10	positive regulation of miRNA maturation	GO:1903800	9.52	TP53 EGFR
11	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.43	MSH2 MLH1
12	somatic recombination of immunoglobulin gene segments	GO:0016447	9.35	MSH6 MSH2 MLH1
13	somatic hypermutation of immunoglobulin genes	GO:0016446	9.23	PMS2 MSH6 MSH2 MLH1

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	10.18	TP53 NKX2-1 MSH6 MSH2 MLH1 EGFR
2	double-stranded DNA binding	GO:0003690	9.98	MSH6 MSH2 EGFR CDX2
3	nucleotide binding	GO:0000166	9.91	NEK8 MSH6 MSH2 MLH1 KRAS HRAS
4	MutLalpha complex binding	GO:0032405	9.78	MSH6 MSH2
5	oxidized purine DNA binding	GO:0032357	9.76	MSH6 MSH2
6	ATP-dependent DNA damage sensor activity	GO:0140664	9.76	PMS2 MSH6 MSH2 MLH1
7	single guanine insertion binding	GO:0032142	9.67	MSH6 MSH2
8	single thymine insertion binding	GO:0032143	9.62	MSH2 MSH6
9	guanine/thymine mispair binding	GO:0032137	9.43	MSH6 MSH2 MLH1
10	mismatched DNA binding	GO:0030983	9.1	PMS2 MSH6 MSH2 MLH1